Akebia Therapeutics Issues Inducement Stock Options
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on enhancing the lives of those affected by kidney disease, has recently made a significant decision to grant stock options to a new employee. This move underscores the company's dedication to building a skilled workforce as it navigates the challenges of biopharmaceutical development.
Stock Options Granted: Key Details
The company has granted options to purchase a total of 4,000 shares of its common stock to the newly hired employee. This grant was made in accordance with the employment agreement and demonstrates Akebia's compliance with Nasdaq Listing Rule 5635(c)(4). On the date of the grant, the exercise price was established at $1.55 per share, which corresponds to the closing price of Akebia's common stock on that day.
Vesting Schedule and Conditions
The stock options come with a defined vesting schedule. Specifically, 25% of the shares will vest after the employee completes their first year with the company. The remaining 75% will vest quarterly over the following years, contingent upon the employee's continued service at Akebia. Each option is valid for ten years and adheres to the guidelines set forth in Akebia's inducement award program, along with the relevant stock option agreement.
About Akebia Therapeutics
Founded in 2007 and based in Cambridge, Massachusetts, Akebia Therapeutics is committed to driving innovation within the biopharmaceutical industry, particularly in the realm of kidney disease. The company aims to develop treatments that significantly enhance patient outcomes and improve their quality of life.
Dedication to Kidney Health
Akebia's research and development initiatives are intensely focused on providing transformative therapies for individuals affected by kidney-related conditions. Their commitment to public health is reflected in their ongoing projects and collaborations aimed at improving patient care.
Contact Information for Inquiries
For more information about Akebia Therapeutics, interested individuals are invited to reach out to:
Mercedes Carrasco
Email: [email protected]
Frequently Asked Questions
What is the purpose of the stock options granted by Akebia?
The stock options serve as an incentive for a newly hired employee, encouraging long-term commitment to the company.
What is Akebia Therapeutics focused on?
Akebia is dedicated to improving the lives of individuals affected by kidney disease through innovative biopharmaceutical solutions.
How long is the vesting period for the stock options?
The stock options have a vesting period of four years, with specific milestones at one year and quarterly thereafter.
Where is Akebia Therapeutics located?
Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
How can I contact Akebia for more information?
You can reach out to Mercedes Carrasco via email at [email protected]
